Clinical Trail of SARS-CoV-2 Bivalent mRNA Vaccine (LVRNA021) as Booster in Participants Aged 18 Years and Older
Status:
Recruiting
Trial end date:
2024-06-01
Target enrollment:
Participant gender:
Summary
This is a multi-center, randomized, blinded, placebo-controlled, phase 3 clinical study to
evaluate the efficacy, safety and immunogenicity of SARS-CoV-2 bivalent mRNA vaccine
(LVRNA021) as booster in participants aged 18 years and older who completed primary/1 booster
dose(s) of SARS-CoV-2 vaccination.
Phase:
Phase 3
Details
Lead Sponsor:
AIM Vaccine Co., Ltd.
Collaborators:
LiveRNA Therapeutics Inc. Ningbo Rongan Biological Pharmaceutical Co. Ltd.